Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.

Trial Profile

Non-randomized, prospective, non-controlled study of changes of lipid parameters after introduction of evolocumab in patients with heterozygous familial hypercholesterolemia under LDL-apheresis therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Aug 2017 Primary endpoint (Comparison of the time constant average levels of LDL-C and apoB during LDL-apheresis and those under evolocumab thereapy.) has been met as per the results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 08 Dec 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top